Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity

Journal of Immunology

Volumn 183, Issue 4, 2009, Pages 2365-2372

  Barber, Amorette ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; RAG1 PROTEIN; TUMOR ANTIGEN; CHIMERIC PROTEIN; CYTOKINE; EPITOPE; KLRK1 PROTEIN, MOUSE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; IMMUNOCOMPETENT CELL; LYMPHATIC DRAINAGE; LYMPHOCYTE COUNT; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; T LYMPHOCYTE; TUMOR IMMUNITY; WILD TYPE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; SECRETION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TRANSPLANTATION; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTANT CHIMERIC PROTEINS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OVARIAN NEOPLASMS; PERFORIN; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 70149097616     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900721     Document Type: Article

References (30)

1. Muranski, P., A. Boni, C. Wrzesinski, D. E. Citrin, S. A. Rosenberg, R. Childs, and N. P. Restifo. 2006. Increased intensity lymphodepletion and adoptive immunotherapy: how far can we go? Nat. Clin. Pract. Oncol. 3: 668-681.
2. June, C. H. 2007. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117: 1204-1212.
3. Leen, A. M., C. M. Rooney, and A. E. Foster. 2007. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25: 243-265.
4. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
5. Sentman, C. L., M. A. Barber, A. Barber, and T. Zhang. 2006. NK cell receptors as tools for cancer immunotherapy. Adv. Cancer Res. 95: 249-292.
6. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
7. Bryceson, Y. T., and H. G. Ljunggren. 2008. Tumor cell recognition by the NK cell activating receptor NKG2D. Eur. J. Immunol. 38: 2957-2961.
8. Blankenstein, T., and Z. Qin. 2003. The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15: 148-154. (Pubitemid 36287519)
9. Marth, C., G. H. Windbichler, H. Hausmaninger, E. Petru, K. Estermann, A. Pelzer, and E. Mueller-Holzner. 2006. Interferon-γ in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16: 1522-1528.
10. Pujade-Lauraine, E., J. P. Guastalla, N. Colombo, P. Devillier, E. Francois, P. Fumoleau, A. Monnier, M. Nooy, L. Mignot, R. Bugat, et al. 1996. Intraperitoneal recombinant interferon γ in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. 14: 343-350.
11. Mantovani, A., P. Romero, A. K. Palucka, and F. M. Marincola. 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
12. Zhang, T., B. A. Lemoi, and C. L. Sentman. 2005. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551.
13. Zhang, T., A. Barber, and C. L. Sentman. 2006. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66: 5927-5933.
14. Barber, A., T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67: 5003-5008.
15. Zhang, T., A. Barber, and C. L. Sentman. 2007. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67: 11029-11036.
16. Barber, A., T. Zhang, and C. L. Sentman. 2008. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host anti-tumor immunity in murine ovarian cancer. J. Immunol. 180: 72-78.
17. Huang, B., J. Zhao, H. Li, K. L. He, Y. Chen, S. H. Chen, L. Mayer, J. C. Unkeless, and H. Xiong. 2005. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65: 5009-5014.
18. Barber, M. A., T. Zhang, B. A. Gagne, and C. L. Sentman. 2007. NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J. Immunol. 178: 6140-6147.
19. Huarte, E., J. R. Cubillos-Ruiz, Y. C. Nesbeth, U. K. Scarlett, D. G. Martinez, R. J. Buckanovich, F. Benencia, R. V. Stan, T. Keler, P. Sarobe, et al. 2008. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 68: 7684-7691.
20. Grundy, M. A., and C. L. Sentman. 2006. Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissues. Exp. Cell Res. 312: 3920-3926.
21. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
22. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
23. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
24. + T cells. J. Exp. Med. 202: 907-912.
25. Williams, K. M., and R. E. Gress. 2008. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract. Res. Clin. Haematol. 21: 579-596.
26. Tey, S. K., C. M. Bollard, and H. E. Heslop. 2006. Adoptive T-cell transfer in cancer immunotherapy. Immunol. Cell Biol. 84: 281-289.
27. Uchi, H., R. Stan, M. J. Turk, M. E. Engelhorn, G. A. Rizzuto, S. M. Goldberg, J. D. Wolchok, and A. N. Houghton. 2006. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv. Immunol. 90: 215-241. (Pubitemid 43765798)
28. Mistry, A. R., and C. A. O'Callaghan. 2007. Regulation of ligands for the activating receptor NKG2D. Immunology 121: 439-447.
29. Borchers, M. T., N. L. Harris, S. C. Wesselkamper, S. Zhang, Y. Chen, L. Young, and G. W. Lau. 2006. The NKG2D-activating receptor mediates pulmonary clearance of Pseudomonas aeruginosa. Infect. Immun. 74: 2578-2586.
30. Ferrantini, M., I. Capone, and F. Belardelli. 2008. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev. 19: 93-107. (Pubitemid 351200063)